Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

*Pre Print Non-Peer Reviewed* “Conclusion: The administration of HCQ did not result in a higher negative conversion rate but more alleviation of clinical symptoms than SOC alone in patients hospitalized with COVID-19 without receiving antiviral treatment, possibly through anti-inflammatory effects. Adverse events were significantly increased in HCQ recipients but no apparently increase of serious adverse events.”


Leave a Reply

Your email address will not be published. Required fields are marked *